drugset / Trial / NCT03801759

Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide

NCT03801759

Phase 1 Completed 62 enrolled Akebia Therapeutics
Non-randomizedSequentialOpen-labelBasic science

Summary

This is a Phase 1, open-label, 3-arm, fixed sequence, study to evaluate vadadustat as a perpetrator of drug-drug interactions (DDIs) with digoxin, adefovir and furosemide in healthy male and female subjects.

Timeline

Start
2018-07-20
Primary completion
2018-09-30
Completion
2018-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Adefovir Unknown 10 mg Oral
Subject Digoxin Other / unclassified 0.5 mg Oral
Subject Furosemide Other / unclassified 40 mg Oral
Subject Vadadustat Small molecule 600 mg Oral

Indications

No indication recorded.